MRO: Global Hereditary Angioedema Market Forecasts Research Report 2017 - 2021


Posted April 25, 2017 by jayshree

MarketReportsOnline.com adds "Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021)" report to its research store.

 
The report entitled “Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021)” provides a detailed analysis of the global hereditary market with analysis of market size by value, growth, segments, etc. The report also includes a detailed regional analysis of the US and Europe hereditary angioedema market comprising of hereditary market by value, segments and growth. Under competitive landscape different products in the global hereditary angioedema market have been compared on basis of various technical parameters.

Complete report available at http://www.marketreportsonline.com/584779.html.

Company Coverage: Shire Plc, iBio,Inc., Pharming Group NV & CSL Limited

Moreover, the report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global hereditary angioedema market has also been forecasted for the years 2017-2021, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

Angioedema can be defined as a disorder in which there is a rapid inflammation of the dermis, subcutaneous tissue, mucosa (cavities surrounding internal organs) and sub mucosal tissues. Angioedema can further be divided into acquired and hereditary angioedema. Acquired angioedema is generally caused due to allergy. On the other hand, hereditary angioedema is caused due to genetic mutation.

Shire Plc, iBio, Inc., Pharming Group NV and CSL Limited are some of the key players operating in the global hereditary angioedema market whose company profiling is done in the report. In this segment of the report, business overview, financial overview and the business strategies of the companies are provided.

Hereditary angioedema (HAE) is defined as a condition highlighted by frequent incidences of severe swelling. It is a rarely inherited disorder. It most commonly affects limbs, face, intestinal and respiratory tract and causes severe swelling in these parts of the body. Low levels of C1 inhibitor, a protein leads to the over activation of bradykinin. Bradykinin is a chemical which is the prime cause the occurrence of angioedema.

The global hereditary angioedema market is projected to increase at a healthy rate during the forecasted period (2017-2021). This growth is expected on account of many growth drivers such as increased diagnosis in the US and Europe, advantages of preventive therapy, approval of Berinert for pediatric treatment, launch of Haegarda C1 inhibitor and some other major products in the pipeline.

Purchase a copy of this “Global Hereditary Angioedema Market: Size, Trends & Forecasts (2017-2021)” research report at USD 800 (Single User License) http://www.marketreportsonline.com/contacts/purchase.php?name=584779.

However, the market also faces certain challenges such as high prophylaxis cost, side effects of Cinryze and long term prophylactic treatment. Oral therapy for hereditary angioedema attacks and SHP643 monoclonal antibody are some of the trends in the global hereditary angioedema market.

Few Points from List of Figures:

Figure 1: Hereditary Angioedema Market Segments
Figure 2: Global Hereditary Angioedema Market by Value; 2016-2021(US$ Billion)
Figure 3: Global Hereditary Angioedema Market by Products; 2016
Figure 4: Global Cinryze Market by Value; 2016-2021 (US$ Million)
Figure 5: Global Haegarda/Berinert Market by Value; 2016-2021 (US$ Million)
Figure 6: Global Acute Therapies (HAE) Market by Value; 2016-2021 (US$ Million)
Figure 7: Global SHP643 Market by Value; 2018-2021 (US$ Million)
Figure 8: Global BX7353 Market by Value; 2020-2021 (US$ Million)
Figure 9: The US Hereditary Angioedema Market by Prevalence; 2016-2021 (Thousands)
Figure 10: The US Hereditary Angioedema Market by Patients Diagnosed; 2016-2021 (Thousands)
Figure 11: The US Hereditary Angioedema Market by Patients on Prophylaxis; 2016-2021
Figure 12: The US Hereditary Angioedema Market by Cost Per Patient; 2016-2021 (US$ Thousands)
Figure 13: The US Hereditary Angioedema Market by Products; 2016
Figure 14: The US Cinryze Market by Value; 2016-2021(US$ Million)
Figure 15: The US Haegarda/Berinert Market by Value; 2016-2021 (US$ Million)

Explore More Related Reports on Pharmaceuticals Market at http://www.marketreportsonline.com/cat/pharmaceuticals-market-research.html.

About Us:
MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Next to Inox Theatre,
Bund Garden Road,
Pune - 411001.
Maharashtra, India.
Tel: + 1 888 391 5441
E-mail: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By MarketReportsOnline
Website Hereditary Angioedema Industry Global Research and Forecasts Analysis 2021
Phone + 1 888 391 5441
Country India
Categories Business
Tags global hereditary angioedema market , hereditary angioedema , hereditary angioedema industry , hereditary angioedema market , hereditary market , pharmaceuticals
Last Updated April 25, 2017